The 22nd annual meeting of the American Society of Gene and Cell Therapy (ASGCT) was held April 29–May 2 in Washington, D.C. with a record number of 4,813 participants, a big jump from the previous record of just over 3,000 attendees. 1,010 abstracts were submitted and 476 oral talks were presented to the audience, which included not only gene and cell therapy researchers and clinicians, but also an increased number of participants from big pharma, start-up companies, and investors interested in the latest developments in gene and cell therapy.